Status:
TERMINATED
A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis
Lead Sponsor:
Pfizer
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To evaluate the efficacy, safety and tolerability of CP-195543 and celecoxib dual therapy in subjects with rheumatoid arthritis
Detailed Description
Trial enrollment was prematurely discontinued on December 3, 2007. The results of an interim efficacy and safety analysis demonstrated an overall poor tolerability profile and high discontinuation rat...
Eligibility Criteria
Inclusion
- A diagnosis of RA based upon the American college of Rheumatology 1987 revised criteria
- Active disease at Screening
- Stable dose of methotrexate between 10-25 mg/week oral or parenteral
Exclusion
- A diagnosis of any other inflammatory or secondary, noninflammatory arthritis that, in the opinion of the Investigator, would interfere with disease activity assessments
- A history of hypersensitivity or allergic type reactions to cyclooxygenase inhibitors, opiates, aspirin or sulfonamides
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00424294
Start Date
June 1 2006
End Date
February 1 2008
Last Update
September 25 2014
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Huntsville, Alabama, United States, 35801
2
Pfizer Investigational Site
Scottsdale, Arizona, United States, 85251
3
Pfizer Investigational Site
Upland, California, United States, 91786
4
Pfizer Investigational Site
Boca Raton, Florida, United States, 33486